Biophytis reports its financial results for the first half of 2025 and provides an update on its strategic outlook.
Stanislas Veillet, Chief Executive Officer of Biophytis, stated: “The first half of 2025 marks a decisive milestone in the execution of our strategy. With the signing of a memorandum of understanding to create a joint venture in Asia, we are paving the way for the world’s first Phase 3 clinical trial in sarcopenia. At the same time, EMBRAPII’s support in Brazil for our Phase 2 obesity trial confirms the potential of BIO101 in combination with GLP-1 therapies. These tangible advances, together with the planned strengthening of our research platform, position Biophytis to sustainably improve the lives of millions of patients and create long-term value for our shareholders.”
